Kiniksa reports Q4/FY 2025 net income; ARCALYST revenue up 62% to $677.6M; guides 2026 $900-920M

Kiniksa Pharmaceuticals International, plc

2025-FY EPS reported $0.75 revenue$677,564,000

ARCALYST net product revenue $202.1M Q4, $677.6M FY 2025 (+62% YoY); gross-to-net improved to 8.4%.
Net income $14.2M Q4, $59.0M FY 2025 vs net loss of $8.9M/$43.2M in prior-year periods.
Cash, cash equivalents & short-term investments $414.1M, no debt, up from $243.6M.
2026 ARCALYST revenue guidance $900-$920M; company expects positive annual cash flow from operations.
KPL-387 Phase 2/3 recurrent pericarditis data expected 2H 2026; KPL-1161 Phase 1 planned by end of 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.